



TANDEM
Diabetes Care



MAY 2, 2024

Company Overview

Safe Harbor

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; our ability to secure and maintain necessary regulatory approvals for our existing products and new products under development. Our estimates and forward-looking statements are based on our management's current assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements are not guarantees of future performance and involve a number of risks and uncertainties, many of which are beyond our control, including the potential impacts of global macroeconomic conditions and our ability to successfully complete, manage and integrate acquisitions with our existing business. Our actual results may differ materially from those expressed or implied by such forward-looking statements. Some of the additional factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent Annual Report on Form 10-K, and in the other reports we file with the Securities and Exchange Commission. In addition, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by law, we undertake no obligation to update or review any estimate and forward-looking statement because of new information, future events or other factors.

TRADEMARKS


©2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem Diabetes, Tandem, t:slim, Tandem Mobi, Mobi, Steadiset, Sigi, Tandem Source, t:slim G4, t:slim X2, Basal-IQ, Control-IQ, t:connect, positively different and our logos are trademarks, registered trademarks, and/or the subject of a pending trademark application in the U.S. and/or other territories worldwide. The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Tandem Diabetes Care is under license. All other trademarks and copyrights are the property of their respective owners.



Tandem Diabetes Care

POSITIVELY DIFFERENT

- + Large and underpenetrated worldwide market
- + Robust portfolio approach, featuring Control-IQ technology, offers choice and optionality
 - t:slim X2 – leadership in automated insulin delivery
 - Sensor integration with Dexom G7 worldwide
 - Abbott Freestyle Libre 2 plus now available in the US
 - Tandem Mobi - expanding our portfolio
 - Tandem Source – our robust data management application
- Scaling renewal opportunity
 - Apx. 450,000 in-warranty customers as of 2023 in 25 countries
- + Committed to R&D investment, while achieving operating leverage and maintaining balance sheet strength
- + Headquartered in San Diego with approximately 2,400 employees worldwide



Christopher
diagnosed 2008



Commercial Products





t:slim Platform

Our flagship insulin pump

Designed for people living with diabetes who want the convenience of an integrated touchscreen device and the flexibility to choose the components of their insulin delivery system (e.g., CGM) to fit a wider range of needs and lifestyles.



Mide
diagnosed 2012



T:SLIM PLATFORM

High-Precision Dosing & Flexibility

- + t:slim X2: #1 rated AID system¹
- + Up to 38% smaller than other manufacturer's durable insulin pumps²
- + 300-unit cartridge
- + Mobile app bolus insulin delivery
- + Choice of 30+ mix-and-match infusion set options





Mobi Platform

EXPANDING OUR PUMP PORTFOLIO

Designed for people who value discretion and simplicity. Mobi is offered with smartphone control¹. It provides greater wearability options, while maximizing discretion and comfort to users, and preserving the ability to disconnect.

- + World's smallest, durable automated insulin delivery system²
- + Next-level wearability: designed for use with a new 5-inch infusion set and on-body adhesive sleeve (sold separately)
- + On-pump insulin delivery button
- + Compatible with Dexcom G6
- + Dexcom G7 expected 2Q 2024, followed by Abbott FreeStyle Libre 3



Ricky
diagnosed 2013





Control-IQ Technology

The #1 rated automated insulin delivery system¹

Control-IQ technology is a predictive algorithm with an automated correction bolus feature that has been shown to provide immediate and sustained results.

- + #1 rated in overall customer satisfaction¹
- + Results from three independent pivotal studies published in the New England Journal of Medicine²



¹dQ&A US Q3 2023 Diabetes Connections Patient Panel Report

² Brown SA, Kovatchev BP, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med 2019; 381:1707-1717. Breton MD, Kanapka LG, et al. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med 2020; 383:836-845.

Wadwa RP, Reed WR, et al. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. N Engl J Med 2023; 388:991-1001.





Tandem Source Platform

Global, next generation data management application

Providing flexible opportunities for customers to engage with data and for HCPs to manage their care.

First element of our vision for better therapy management leveraging next generation digital assets.

- + U.S. launch completed in 2023
- + Additional countries launching in 2024



Brittney
diagnosed 2008



Tandem Source

A MULTI-SIDED PLATFORM

PATIENTS & CAREGIVERS

Data Management

- + Reporting
- + Decision Support*




Customer Experience

- + Supplies Ordering
- + Software Update
- + Device Management
- + Account Management
- + Customer Support



ADMINS


Patient and Device Management



CLINICIANS

Patient Engagement

- + Reporting
- + Patient Monitoring
- + Decision Support



Data Upload

*Feature under development, not available at launch.





Goals & Growth Drivers



Serving a Large Underpenetrated Market

- + People living with type 1 diabetes in the U.S. and 25 international countries ¹
 - Less than 40% of the ~1.9M people living with type 1 diabetes in the U.S. use an insulin pump
 - Less than 20% of the ~3M people living with type 1 diabetes in the countries we serve use a pump
- + People living with type 2 diabetes who require intensive insulin therapy (IIT)
 - Approximately 5% of the ~2M people living with type 2 IIT in the U.S. use an insulin pump ¹

Diabetes	Type 1	Type 2
Cause	Autoimmune: Body does not create insulin hormone	Lifestyle/Genetics: Insulin resistance where cells do not use insulin properly
Onset	Sudden: Typically before age 40	Progressive: Typically appears later in life
Prevention	None	Diet and exercise
Therapy	Insulin	Oral medication, injectables, insulin

¹2023 Internal estimates factoring some data from the International Diabetes Federation and Centers for Disease Control and Prevention (CDC).




Scaling Renewal Opportunity

- + High customer satisfaction resulting in strong U.S. retention and rate of renewal
- + Goal of ~70% renewal rate consistently being achieved in the U.S. within ~18 months following the expiration of a customer's warranty

Renewal Metrics

- + 2023 U.S. renewal shipments increased approximately 50% YOY
- + More than 50% of t:slim U.S. customers eligible up for renewal in 2023 renewed within the year
- + Typical warranty period is 4 years; average customer renewal cycle is 5 years
- + In early stages of OUS renewal cycle; do not anticipate meaningful contribution in 2024



Robust Product Pipeline

Insulin
Pumps



Advanced
Algorithms




Digital
Experiences



- + Portfolio designed to expand market and capture share
- + Robust portfolio approach to offer choice and optionality
- Began the launch of 4 new products in Q4 2023 and Q1 2024
 - Tandem Mobi launched in the U.S.
 - Scaling worldwide launch of t:slim X2 with Dexcom G7 integration
 - t:slim X2 now available in the U.S with Abbott FreeStyle Libre 2 Plus integration
 - U.S. launch of Tandem Source



Driving Growth THROUGH INNOVATION & CUSTOMER SATISFACTION





Longer-Term Targets¹

- + 1 million customers worldwide
 - Approximately 450,000 in-warranty customers as of December 31, 2023
- + 65% Gross margin
 - Expected to be mostly correlated to the adoption of Tandem Mobi² and extended wear infusion sets³
- + 25% Operating margin



Tristan
diagnosed 1997





Robust Pipeline




PORTFOLIO APPROACH FOR

Meeting Different Needs & Preferences



Expand Beyond the Early Adopters

OUR PORTFOLIO APPROACH



t:slim Platform



Mobi Platform



Sigi Platform



Control-IQ
Technology



Software
Updates



Wireless
Data Uploads



Multiple CGM
Integrations



Disconnect Variety
of Infusion Sets




TANDEM MOBI PLATFORM

Tubeless Infusion Site Feature

Driving greater penetration in the market segment that Tandem Mobi serves.

- + Ultimate in choice of wearability
- + Modular components
- + Adds new options in wearability
- + Disconnect and reconnect
- + Insulin recovery





Sigi Platform

Redefining patch pump therapy for diabetes


Sigi is designed to be a low-profile, ergonomic, and easy-to-use insulin pump for people who prefer an infusion site without tubing. It provides the wearability of a patch pump without compromising the flexibility and sustainability of a durable pump.



SIGI PLATFORM

Wearability of a Patch, Flexibility of a Durable

- + Novel detachability
- + Pre-filled cartridges
- + Reduced environmental impact
- + Extended-wear options
- + Form factor and ease of use designed to expand both type 1 and type 2 diabetes adoption



UNMATCHED SYSTEM CUSTOMIZATION


Extended Wear Infusion Set

- + 7-day infusion set with reliable insulin delivery technology
- + Innovative cannula design
 - Kink resistant
 - Soft cannula material
 - Additional delivery side ports
- + Compact and easy-to-use inserter
 - Hidden needle
 - Sharp Safe disposal
- + Compatible with t:slim and Mobi platforms



A1D Improvement

GROWING THE MARKET BY REDUCING DIABETES BURDEN



Note: Next-generation closed loop technology and future features are under development and subject to future regulatory submission and clearance.






Glycemic Outcomes

For people with type 2 diabetes using GLP-1 and/or SGLT-2 therapy in addition to insulin.

Results highlight benefit of Control-IQ Technology with GLP-1 therapy

Improvement in Time in Range in the 2IQ Study





Summary & Financials



Pricing Overview

- + Reimbursement differs by customer insurance plan, geography and product
- + Total amount realized per patient is approximately the same in a four-year reimbursement cycle


	Domestic	OUS
% Distributor	~65%	~95%
Pump 1 reimbursed every 4 years	~\$4K	\$2K - \$3K
Supplies 120 cartridges and infusion sets used per patient per year	\$4K	\$5K
Total Realized per Patient at projected near-term distributor mix	\$8K	\$7K - \$8K



Tandem Diabetes Care

POSITIVELY DIFFERENT

- + Large and underpenetrated worldwide market
- + Robust portfolio approach, featuring Control-IQ technology, offers choice and optionality
 - t:slim X2 – leadership in automated insulin delivery
 - Sensor integration with Dexom G7 worldwide
 - Abbott Freestyle Libre 2 plus now available in the US
 - Tandem Mobi - expanding our portfolio
 - Tandem Source – our robust data management application
- Scaling renewal opportunity
 - Apx. 450,000 in-warranty customers as of 2023 in 25 countries
- + Committed to R&D investment, while achieving operating leverage and maintaining balance sheet strength
- + Headquartered in San Diego with approximately 2,400 employees worldwide



Christopher
diagnosed 2008

Tandem

Diabetes Care

Investor Relations:

858-366-6900

IR@tandemdiabetes.com

